Edesa Biotech is trading 8.04% higher in after-hours at $3.18 after closing the regular session at $2.94, with no fresh company-specific catalyst identified for the move.
- The after-hours rebound followed a sharp regular-session decline.
- The reported $25 million public offering appeared in earlier coverage, not as a new October 12 announcement; available search results show no clear same-day release explaining the move.
- Broader indices were mixed, so market direction does not clearly explain the gain.